Evolus (EOLS +15.9%) is up on 70% higher volume in reaction to the rapid enrollment in its Jeuveau Experience Treatment program. More than 3,000 provider accounts signed up in three weeks and 67% of patients switched from market leader BOTOX from Allergan (AGN -1.9%). Enrollment in J.E.T. will wind up on June 28.
On July 1, it will launch #NEWTOX NOW that will offer consumers $75 to help pay for treatment at participating practices. The company says both programs have it “on track” to achieve the #2 market position in the U.S. within 24 months of launch.
The FDA approved Jeuveau (prabotulinumtoxinA-xvfs) in May for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines) in adults.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.